ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
REGENXBIO Inc

REGENXBIO Inc (RGNX)

12.53
-0.42
(-3.24%)
At close: September 18 4:00PM
12.53
-0.02
( -0.16% )
After Hours: 4:48PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
12.53
Bid
12.50
Ask
13.30
Volume
605,179
12.29 Day's Range 13.01
10.49 52 Week Range 28.80
Market Cap
Previous Close
12.95
Open
12.94
Last Trade Time
16:03:17
Financial Volume
$ 7,615,835
VWAP
12.5844
Average Volume (3m)
475,171
Shares Outstanding
49,423,188
Dividend Yield
-
PE Ratio
-2.35
Earnings Per Share (EPS)
-5.33
Revenue
90.24M
Net Profit
-263.49M

About REGENXBIO Inc

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neur... Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
-
REGENXBIO Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker RGNX. The last closing price for REGENXBIO was $12.95. Over the last year, REGENXBIO shares have traded in a share price range of $ 10.49 to $ 28.80.

REGENXBIO currently has 49,423,188 shares outstanding. The market capitalization of REGENXBIO is $640.03 million. REGENXBIO has a price to earnings ratio (PE ratio) of -2.35.

RGNX Latest News

REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

REGENXBIO Appoints Mitchell Chan as Chief Financial Officer PR Newswire ROCKVILLE, Md., Sept. 17, 2024 Life sciences veteran Mitchell Chan joins the company ahead of multiple catalysts across...

REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect

REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect PR Newswire ROCKVILLE, Md., Sept. 3, 2024 -Β  Data from pivotal dose level demonstrates...

REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire ROCKVILLE, Md., Aug. 29, 2024 ROCKVILLE, Md., Aug. 29, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it...

REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium PR Newswire ROCKVILLE, Md., Aug. 27, 2024 ROCKVILLE, Md., Aug. 27, 2024...

REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference PR Newswire ROCKVILLE, Md., Aug. 8, 2024 ROCKVILLE, Md., Aug. 8, 2024 /PRNewswire/ -- REGENXBIO Inc...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.867.3693230505611.6713.4811.55545268012.72866996CS
40.554.5909849749611.9813.4811.0840299211.98764924CS
120.312.5368248772512.2215.3610.4947517112.4252634CS
26-9.6-43.380027112522.1323.1410.4949040414.49885665CS
52-5.42-30.194986072417.9528.810.4956055216.4079566CS
156-31.39-71.47085610243.9245.1710.4944992721.58847571CS
260-26.42-67.830551989738.9554.9710.4943821627.87416336CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
XCURExicure Inc
$ 6.76
(195.20%)
5.85M
VEROVenus Concept Inc
$ 0.76
(51.24%)
4.28M
TBIOTelesis Bio Inc
$ 1.943
(42.87%)
561.57k
ZEOZeo Energy Corporation
$ 1.59
(39.47%)
72.5k
INDPIndaptus Therapeutics Inc
$ 1.60
(13.48%)
1.17k
SMFLSmart for Life Inc
$ 0.57
(-26.92%)
1.4M
OMEXOdyssey Marine Exploration Inc
$ 1.18
(-15.71%)
3.16M
CRMTAmericas Car Mart Inc
$ 44.00
(-11.93%)
4.7k
SMSISmith Micro Software Inc
$ 0.915
(-10.29%)
165.81k
KLTOKlotho Neurosciences Inc
$ 0.8129
(-8.66%)
864
XCURExicure Inc
$ 6.76
(195.20%)
5.85M
NVDANVIDIA Corporation
$ 113.35
(-0.02%)
5.28M
VEROVenus Concept Inc
$ 0.76
(51.24%)
4.28M
OMEXOdyssey Marine Exploration Inc
$ 1.18
(-15.71%)
3.19M
EJHE Home Household Service Holdings Ltd
$ 0.1018
(-3.96%)
2.75M

RGNX Discussion

View Posts
crudeoil24 crudeoil24 3 years ago
36M share trading float.

RGNX
πŸ‘οΈ0
crudeoil24 crudeoil24 3 years ago
AbbVie And REGENXBIO Announce Eye Care Collaboration; AbbVie To Pay REGENXBIO $370M Upfront Payment And Up To $1.38B In milestones
6:31 am ET September 13, 2021 (Benzinga) Print
AbbVie (NYSE:ABBV) and REGENXBIO Inc. (NASDAQ:RGNX) today announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. RGX-314 is currently being evaluated in patients with wet AMD in a pivotal trial utilizing subretinal delivery, and in patients with wet AMD and DR in two separate Phase II clinical trials utilizing in-office suprachoroidal delivery.

Under the collaboration, REGENXBIO will be responsible for completion of the ongoing trials of RGX-314. AbbVie and REGENXBIO will collaborate and share costs on additional trials of RGX-314, including the planned second pivotal trial evaluating subretinal delivery for the treatment of wet AMD and future trials. AbbVie will lead the clinical development and commercialization of RGX-314 globally. REGENXBIO shall participate in U.S. commercialization efforts as provided under a mutually agreed upon commercialization plan.

"We are committed to finding solutions for patients living with difficult-to-treat retinal diseases and to helping preserve and protect our patients from visual impairment and devastating vision loss," said Tom Hudson, MD, senior vice president, R&D, chief scientific officer, AbbVie. "In collaboration with REGENXBIO, we aim to make a remarkable impact for the millions of patients suffering from vision loss associated with retinal diseases."

"AbbVie is a strong, complementary partner for REGENXBIO. We expect to leverage AbbVie's global developmental and commercial infrastructure within eye care with our expertise in AAV gene therapy clinical development and deep in-house knowledge of manufacturing and production to continue the development of RGX-314," said Kenneth T. Mills, president and chief executive officer of REGENXBIO.

Under the terms of the agreement, AbbVie will pay REGENXBIO a $370 million upfront payment with the potential for REGENXBIO to receive up to $1.38 billion in additional development, regulatory and commercial milestones. REGENXBIO and AbbVie will share equally in profits from net sales of RGX-314 in the U.S. AbbVie will pay REGENXBIO tiered royalties on net sales of RGX-314 outside the U.S. In addition, REGENXBIO will lead the manufacturing of RGX-314 for clinical development and U.S. commercial supply, and AbbVie will lead manufacturing of RGX-314 for commercial supply outside the U.S.
πŸ‘οΈ0
StockLearner2011 StockLearner2011 5 years ago
https://www.google.com/amp/s/www.nasdaq.com/article/4-gene-therapy-players-likely-to-become-buyout-targets-in-2019-cm1125990/amp
πŸ‘οΈ0
StockLearner2011 StockLearner2011 5 years ago
I believe the buyout is in a distance future. JUNO has the same trading behavior before buyout was announced!
πŸ‘οΈ0
Zmill Zmill 5 years ago
is there an argument for a BO? https://msmoneymoves.com/2019/05/28/could-this-biotech-stock-get-bought-for-5-5-billion-either-way-im-buying-it/
πŸ‘οΈ0
BlackEyePatch BlackEyePatch 5 years ago
Strong buy @ 50!!!!
πŸ‘οΈ0
stocktrademan stocktrademan 6 years ago
RGNX buy 66.90























normal chart




log chart



πŸ‘οΈ0
StockLearner2011 StockLearner2011 6 years ago
Hope no more form 4s for insider selling
πŸ‘οΈ0
StockLearner2011 StockLearner2011 6 years ago
Let’s see how tomorrow will be
πŸ‘οΈ0
StockLearner2011 StockLearner2011 6 years ago
Why insiders sold at $34 and $37 while the target price is $90? Anybody has any clue?
πŸ‘οΈ0
StockLearner2011 StockLearner2011 6 years ago
$45 soon! Yummy
πŸ‘οΈ0
stocktrademan stocktrademan 8 years ago
RGNX bullish 14.39



normal chart


log chart

πŸ‘οΈ0
protagonist12 protagonist12 8 years ago
Agreed, would like to to see the stock come down to single digits before buying though. Still only in preclinical trials and burning a ton of cash.
πŸ‘οΈ0
floWteiuQ floWteiuQ 8 years ago
Interesting play here for the long term. Very good technology with a lot of prospects for them and licensing.
πŸ‘οΈ0
protagonist12 protagonist12 9 years ago
RGNX no bid support, too early still, listed VC...
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock